A Korean research team has developed a new viral vector technology that significantly improves the production efficiency of next-generation cell and gene therapies known as CAR immune cell therapies, ...
Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the development and commercialization of scalable microbial ...
Predictive biomarkers remain a key foundation of personalized medicine, enabling the identification of patients most likely ...
Researchers at the University of California San Diego have developed a large-scale screening approach that identifies ...
Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery and development through innovative ...
Bolsters Japan Market Expansion, Strategic Collaborations and Demand for Scalable Recombinant Protein SolutionsJUPITER, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI ...
A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...
Two proteins with opposing functions orchestrate the development and maintenance of healthy skin, Stanford Medicine ...
This article explores how new technologies in plasma proteomics enable the simultaneous analysis of thousands of proteins, ...
Predictive biomarkers remain a key foundation of personalized medicine, enabling the identification of patients most likely ...
New study identifies CAR3 as a key osteoblast protein promoting collagen mineralization, bone formation, and skeletal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results